CFGS
RVNC

Concourse Financial Group Securities’s Revance Therapeutics, Inc. RVNC Stock Holding History

Concourse Financial Group Securities’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-570
Closed -$2.08K – 2236
2024
Q4 		$2.08K Hold
570
– – ﹤0.01% 2012
2024
Q3 		$2.96K Hold
570
– – ﹤0.01% 1948
2024
Q2 		$1.46K Hold
570
– – ﹤0.01% 2075
2024
Q1 		$2.8K Buy
+570
New +$3.37K ﹤0.01% 1999
2022
Q1 		– Sell
-500
Closed -$7.58K – 2472
2021
Q4 		$8K Hold
500
– – ﹤0.01% 1941
2021
Q3 		$14K Hold
500
– – ﹤0.01% 1792
2021
Q2 		$15K Hold
500
– – ﹤0.01% 1745
2021
Q1 		$14K Hold
500
– – ﹤0.01% 1680
2020
Q4 		$14K Hold
500
– – ﹤0.01% 1590
2020
Q3 		$13K Hold
500
– – ﹤0.01% 1505
2020
Q2 		$12K Buy
+500
New +$9.87K ﹤0.01% 1448

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Concourse Financial Group Securities's RVNC Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 570 shares — an estimated $2.08K sold.

Concourse Financial Group Securities first reported a position in RVNC in Q2 2020 and held it in 11 quarters. The position peaked at $15K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 570 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $2.08K.
  • Concourse Financial Group Securities first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
  • Concourse Financial Group Securities's Revance Therapeutics, Inc. position peaked at $15K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.